Britain will reportedly infect healthy volunteers with coronavirus in COVID-19 vaccine 'challenge' trials
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
You are now subscribed
Your newsletter sign-up was successful
The British government is on the verge of approving and funding the first clinical trials of COVID-19 vaccines in which healthy volunteers are deliberately infected with live coronavirus, the Financial Times reports. Such "challenge trials" are not new — they have been conducted since the 1790s — but they are more dangerous than double-blind placebo studies and therefore more rare. Still, 2,000 people have signed up to participate in the proposed trials in east London, FT reports, and Britain could green-light the research as soon as next week.
The volunteer subjects will be young, healthy, and deemed at low risk of being harmed by exposure to the new coronavirus. They will first be given a dose of the experimental vaccine and then later get a "challenge" dose of the coronavirus, to see if the vaccine works, FT reports. Imperial College London will reportedly be the academic lead on the trials. It's not clear which vaccines will be tested at the proposed new London quarantine facility, but AstraZeneca and Sanofi both told Reuters they are not involved.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
